哌拉西林舒巴坦治疗先天性心脏病婴儿肺炎的疗效分析

目的:评价哌拉西林舒巴坦(PIP/SBT)经验性治疗先天性心脏病(左向右分流型)(CHD)婴儿肺炎的临床疗效和安全性,为治疗先天性心脏病婴儿肺炎准确合理选用抗菌药提供参考。方法:选择某三级医院2015年～2018年儿科A、B两组医生收治228例有CHD患发肺炎的患儿为研究对象,在对症支持治疗的基础上,A组117例为观察组,给予PIP/SBT抗感染治疗。B组111例为对照组,给予拉氧头孢抗感染治疗。观察两组的治疗效果、细菌清除率、药物不良反应。结果:PIP/SBT治疗组痊愈率为69.2%,临床总有效率为90.6%,细菌清除率为88.3%,不良反应发生率为3.41%。拉氧头孢治疗组分别为44.1%,81.0%,62.5%,2.7%。两组比较差异有统计学意义(P<0.05),治疗效果治疗组PIP/SBT优于对照组拉氧头孢,细菌清除率治疗组PIP/SBT高于对照组拉氧头孢;两组不良反应差异无统计学意义。结论:PIP/SBT治疗先天性心脏病婴儿肺炎有效、安全、不良反应发生率低。值得作为治疗先天性心脏病婴儿肺炎经验性备选药。

Efficacy of Piperacillin sulbactam in the Treatment of Infantile Pneumonia with Congenital Heart Disease

Objective:To evaluate the clinical efficacy and safety of piperacillin sulbactam(PIP/SBT)in the treatment of infantile pneumonia with congenital heart disease(left to right shunt),and to provide a reference for the treatment of infantile pneumonia with congenital heart disease.Methods:228 cases of children with pneumonia combined with congenital heart disease were treated in the two groups of Pediatrics A and B in a hospital from 2015 to 2018.On the basis of the symptomatic support treatment,117 cases of children in group A were treated as the observation group,and the anti infection treatment was given to PIP/SBT.In group B,rate and adverse drug reactions were observed in the two groups.Results:the cure rate of PIP/SBT treatment group was 69.2%,the total effective rate was 90.6%,the bacterial clearance rate was 88.3%,and the incidence of adverse reactions was 3.41%.The children in the treatment group were 44.1%,81.0%,62.5%and 3.41%respectively.The difference between the two groups was statistically significant(P<0.05)The PIP/SBT of the treatment group was better than that of the control group,and the bacterial clearance rate of the treatment group was higher than that of the control group;the difference between the two groups was not statistically significant.Conclusion:PIP/SBT is effective and safe in treating infantile pneumonia complicated with CHD,and the incidence of adverse reactions is low.It is worthy of being used as an empiric alternative drug for the treatment of infantile pneumonia with CHD.